Singapore markets closed

Johnson & Johnson (JNJ)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
157.96+2.19 (+1.41%)
At close: 04:00PM EDT
158.19 +0.23 (+0.15%)
Pre-market: 07:00AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close155.77
Open155.99
Bid157.52 x 800
Ask157.89 x 800
Day's range155.44 - 158.22
52-week range144.95 - 175.97
Volume8,373,625
Avg. volume7,131,095
Market cap380.649B
Beta (5Y monthly)0.53
PE ratio (TTM)30.38
EPS (TTM)5.20
Earnings date16 Apr 2024
Forward dividend & yield4.76 (3.01%)
Ex-dividend date16 Feb 2024
1y target est176.06
  • Reuters

    UPDATE 3-J&J can contest evidence linking its talc to cancer, US judge rules

    Johnson & Johnson will get a new chance to contest the scientific evidence linking talc to ovarian cancer, a federal judge ruled on Wednesday, potentially disrupting more than 53,000 lawsuits the company is now facing over its talc products. In a brief written order, U.S. District Judge Michael Shipp in Trenton, New Jersey, who is overseeing the lawsuits that have been consolidated in his court, said recent changes in the law and new scientific evidence require a fresh review of the evidence that linked J&J products to ovarian cancer. Shipp took over the case in February 2023, after the retirement of former Chief District Judge Freda Wolfson, who had overseen the litigation since 2016.

  • Reuters

    J&J can contest evidence linking its talc to cancer, US judge rules

    NEW YORK (Reuters) -Johnson & Johnson will get a new chance to contest the scientific evidence linking talc to ovarian cancer, a federal judge ruled on Wednesday, potentially disrupting more than 53,000 lawsuits the company is now facing over its talc products. In a brief written order, U.S. District Judge Michael Shipp in Trenton, New Jersey, who is overseeing the lawsuits that have been consolidated in his court, said recent changes in the law and new scientific evidence require a fresh review of the evidence that linked J&J products to ovarian cancer. Shipp took over the case in February 2023, after the retirement of former Chief District Judge Freda Wolfson, who had overseen the litigation since 2016.

  • Zacks

    Merck (MRK) Gets FDA Approval for New PAH Drug Winrevair

    Merck's (MRK) Winrevair becomes the first novel activin signaling inhibitor approved by the FDA to treat PAH.